CStone Pharmaceuticals (HKG:2616) agreed to give commercialization rights for its sugemalimab in ten Latin American countries to Latin American pharmaceutical company SteinCares, a Jan. 27 Hong Kong bourse filing said.
Under the commercialization agreement, SteinCares will handle the regulatory affairs and commercialization activities in Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala, and Ecuador.
The company will receive upfront, regulatory, and commercial milestone payments, along with book revenue from the overseas partner through the supply of the said drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.